Positive Preclinical Data with Transition Therapeutics Alzheimer's Disease Drug Candidate AZD-103

14-Jun-2006

Transition Therapeutics Inc. announced that Nature medicine has published an online version of a publication of preclinical studies with Transition's lead Alzheimer's disease drug candidate, AZD-103. The AZD-103 compound is a possible disease-modifying therapeutic drug candidate for the treatment of Alzheimer's disease. This unique class of drug candidates may provide significant advantages over the current therapies on the market. The findings in the Nature Medicine publication show that oral treatment of AZD-103 (scyllo-cyclohexanehexol) reduces accumulation of amyloid beta and amyloid beta plaques in the brain, as well as reduces or eliminates learning deficits in a transgenic mouse model of Alzheimer's disease. Transition is pursuing the clinical drug development of AZD-103 in an expedited manner.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance